Developer docs
API playgroundTry for free, no card

Search company profiles

quadraScope

Full company profile

uuid000awlb

Namestring
quadraScope
Legal namestring
quadraScope Ventures
Websiteurl
quadrascope.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

quadraScope Ventures is an early-stage venture capital firm founded in 2022 and headquartered in Boston, Massachusetts, with a strategic presence in Tel Aviv, Israel. The firm invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. Its investment thesis is grounded in the Hallmarks of Aging framework introduced by López-Otín et al., and it deploys capital across longevity biotech approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, regenerative medicine, and biomarker platforms.

The firm's operating team is small — Managing Partner Fiona Miller, Scientific Director José Navarro-Betancourt, and Financial Analyst Eve Voronkina — and is augmented by a Scientific Advisory Board of globally recognized longevity researchers (Nir Barzilai, Aubrey de Grey, Carmela Abraham, Robert Cargill, Diane Seimetz, Reason, Nikola Markov, Shailesh Chavan) and a Business Advisory Board of operators and investors (Miri Polachek, Nico Helling, Frank Wellens, Daniel Fylstra, Lan Clark, José Cordeiro, Noriko Yokoi). Its portfolio spans approximately 11 companies, including Immunis (stem cell secretome for muscle atrophy), BioChange (regenerative collagen), Alden Scientific (ML-based personalized medicine), Matter Bio (DNA repair), Deciduous Therapeutics (senolytics), Repair Biotechnologies (cholesterol degradation), Vincere Bio (mitochondrial health), Cosmica Bio (organoids), Healthy Longevity Clinic, Advantag Therapeutics (Klotho gene therapy), and BIOIO (lipid metabolism).

As a venture fund, quadraScope generates revenue through traditional fund economics: management fees (typically 2% of committed capital) and carried interest (typically 20% of profits above a hurdle) on successful portfolio exits. Capital is distributed via direct equity investments in early-stage companies; deal sourcing is supported through industry conferences (JPM Healthcare Week, Longevity Nation, RESI Boston), a YouTube interview channel with longevity KOLs, and engagement with scientific community in the Boston-Tel Aviv corridor. No fund size, AUM, or revenue figures have been publicly disclosed.

Short descriptiontext

quadraScope Ventures is an early-stage venture capital firm founded in 2022 and based in Boston with a Tel Aviv presence, investing in longevity biotechnology companies developing therapeutics, diagnostics, and devices for biological age reversal, supported by a Scientific Advisory Board of leading aging researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital fund, longevity biotechnology, early-stage healthcare investments, biotech portfolio management, rejuvenation medicine investing
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code4 codes
  • Portfolio Management and Investment Advice523940
  • Portfolio Management and Investment Advice52394
  • Funds, Trusts, and Other Financial Vehicles525
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital - Longevity Biotechnology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Fund Management
TypeLicensing Royalties
Description

Generates returns through equity investments in early-stage longevity biotechnology companies. Revenue derived from management fees and carried interest (performance fees) on successful exits.

quadrascope.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

quadraScope Ventures is a venture capital firm that invests in early-stage healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. The firm manages capital and deploys equity into longevity biotechnology startups, provides strategic guidance and scientific due diligence, and supports portfolio companies in clinical development and regulatory pathways. Revenue is generated through management fees and carried interest on successful exits.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 12x return on octoScope exit
Product overview1 text field

quadraScope Ventures is a venture capital firm that invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices enabling disease treatment and prevention through biological age reversal. As an investment fund, quadraScope does not offer products or services to end customers in the traditional sense. The company focuses on identifying and funding early-stage longevity biotechnology companies across various approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, and regenerative medicine. The firm's portfolio includes investments in companies such as Immunis, BioChange, Aldens Scientific, MatterBio, Deciduous Therapeutics, Repair Biotechnologies, Vincere Bio, Cosmica, Healthy Longevity Clinic, AdvantAge Therapeutics, and BIOIO. The investment strategy is grounded in the Hallmarks of Aging scientific framework.

Product and service1 record
1quadraScope Ventures Investment Fund
CategoryVenture Capital Fund
Description

Early-stage venture capital fund that provides equity capital, scientific due diligence, and strategic support to longevity biotechnology startups developing treatments targeting the Hallmarks of Aging. Limited partners commit capital; returns generated through exits.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Klogenix
Strategic tierPortfolio CompanyTypeOthers
Description

Portfolio company developing gene therapy using Klotho protein to treat aging and Alzheimer's disease. Co-founded by Carmela Abraham, PhD, who serves on quadraScope's Scientific Advisory Board and discovered that Klotho protein levels decrease with age and are neuroprotective.

quadrascope.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Biomedical research charity focused on repairing molecular and cellular damage of aging. Scientific founder Aubrey de Grey serves on quadraScope's Scientific Advisory Board. SENS approach aligns with quadraScope's investment thesis on addressing hallmarks of aging.

3Longevity Escape Velocity Foundation
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Foundation led by Aubrey de Grey working on rejuvenation research. President & CSO noted that quadraScope encouraged formation of rejuvenation clinics and has been active in defining treatment protocols as strategic pillar alongside clinical trials.

quadrascope.com
Strategic tierPortfolio CompanyTypeOthers
Description

Portfolio company developing immune system restoration for muscle building, fat reduction, and treating obesity. Chairman Hans Keirstead cited strategic alignment with quadraScope's vision of extending lifespan and healthspan while treating diseases.

Strategic tierPortfolio CompanyTypeOthers
Description

Portfolio company operating franchise of clinics specializing in personalized rejuvenation treatments and offshore clinical trials. CEO Petr Sramek serves on quadraScope's Business Advisory Board.

Strategic tierPortfolio CompanyTypeOthers
Description

Portfolio company developing cholesterol degradation platform to reverse atherosclerosis and fatty liver disease. Co-founder Reason serves on quadraScope's Scientific Advisory Board and is a long-standing investor in longevity industry.

Strategic tierIndustryTypeStrategic or Co-development Partner
Description

Consortium established to develop reliable biomarkers of aging for identification and validation of longevity interventions. quadraScope presented posters at 2023 Biomarkers of Aging Symposium.

8Longevity Biotechnology Association
Strategic tierIndustryTypeOthers
Description

Industry association for longevity biotechnology companies. quadraScope nominated to join in November 2022.

quadrascope.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Early-stage VC investing specifically in longevity and aging biotech, mirroring quadraScope's thesis on hallmarks-of-aging interventions.

TypeDirect peer
Description

Germany-based seed investor dedicated to rejuvenation biotech startups, directly comparable in stage and longevity focus.

TypeDirect peer
Description

Early-stage venture fund backing longevity and biotech founders, sharing quadraScope's specialist focus and stage.

TypeDirect peer
Description

Sergey Young's fund investing in technologies that extend healthy human lifespan, directly overlapping quadraScope's sector thesis.

TypeDirect peer
Description

Mission-driven fund investing in companies extending healthspan, closely aligned with quadraScope's rejuvenation focus.

TypeDirect peer
Description

Seed-stage fund and accelerator (successor to The Longevity Fund) focused on aging biology startups, a direct longevity-specialist peer.

TypeDirect peer
Description

AI and longevity-focused venture fund backing aging and healthspan startups, overlapping quadraScope's investment domain.

TypeRegional player
Description

Swiss longevity company builder and investor in healthy-aging ventures; comparable thesis but centered in Europe.

9Cambrian Biopharma
TypeEmerging player
Description

Builds and funds a portfolio of aging-disease therapeutics companies, overlapping quadraScope's longevity portfolio approach via a different (build) model.

TypeBroad incumbent
Description

Larger longevity-focused company builder and investor developing aging therapeutics, operating broadly across the same rejuvenation space as quadraScope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

quadraScope

Venture Capital - Longevity Biotechnologyquadrascope.com

quadraScope Ventures is an early-stage venture capital firm founded in 2022 and based in Boston with a Tel Aviv presence, investing in longevity biotechnology companies developing therapeutics, diagnostics, and devices for biological age reversal, supported by a Scientific Advisory Board of leading aging researchers.

What quadraScope does

quadraScope Ventures is an early-stage venture capital firm founded in 2022 and headquartered in Boston, Massachusetts, with a strategic presence in Tel Aviv, Israel. The firm invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. Its investment thesis is grounded in the Hallmarks of Aging framework introduced by López-Otín et al., and it deploys capital across longevity biotech approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, regenerative medicine, and biomarker platforms.

The firm's operating team is small — Managing Partner Fiona Miller, Scientific Director José Navarro-Betancourt, and Financial Analyst Eve Voronkina — and is augmented by a Scientific Advisory Board of globally recognized longevity researchers (Nir Barzilai, Aubrey de Grey, Carmela Abraham, Robert Cargill, Diane Seimetz, Reason, Nikola Markov, Shailesh Chavan) and a Business Advisory Board of operators and investors (Miri Polachek, Nico Helling, Frank Wellens, Daniel Fylstra, Lan Clark, José Cordeiro, Noriko Yokoi). Its portfolio spans approximately 11 companies, including Immunis (stem cell secretome for muscle atrophy), BioChange (regenerative collagen), Alden Scientific (ML-based personalized medicine), Matter Bio (DNA repair), Deciduous Therapeutics (senolytics), Repair Biotechnologies (cholesterol degradation), Vincere Bio (mitochondrial health), Cosmica Bio (organoids), Healthy Longevity Clinic, Advantag Therapeutics (Klotho gene therapy), and BIOIO (lipid metabolism).

As a venture fund, quadraScope generates revenue through traditional fund economics: management fees (typically 2% of committed capital) and carried interest (typically 20% of profits above a hurdle) on successful portfolio exits. Capital is distributed via direct equity investments in early-stage companies; deal sourcing is supported through industry conferences (JPM Healthcare Week, Longevity Nation, RESI Boston), a YouTube interview channel with longevity KOLs, and engagement with scientific community in the Boston-Tel Aviv corridor. No fund size, AUM, or revenue figures have been publicly disclosed.

quadraScope firmographics

Firmographics
Name
quadraScope
Legal name
quadraScope Ventures
Website
https://quadrascope.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
quadraScope Ventures is an early-stage venture capital firm founded in 2022 and based in Boston with a Tel Aviv presence, investing in longevity biotechnology companies developing therapeutics, diagnostics, and devices for biological age reversal, supported by a Scientific Advisory Board of leading aging researchers.
Ownership category
akta.pro rank

quadraScope industry classification

Industry
Product category
Venture Capital - Longevity Biotechnology
NAICS
Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Venture capital fund
  • Longevity biotechnology
  • Early-stage healthcare investments
  • Biotech portfolio management
  • Rejuvenation medicine investing

Where quadraScope is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

quadraScope business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Fund Management: Generates returns through equity investments in early-stage longevity biotechnology companies. Revenue derived from management fees and carried interest (performance fees) on successful exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

quadraScope product offering

Product offering

Core offering

quadraScope Ventures is a venture capital firm that invests in early-stage healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. The firm manages capital and deploys equity into longevity biotechnology startups, provides strategic guidance and scientific due diligence, and supports portfolio companies in clinical development and regulatory pathways. Revenue is generated through management fees and carried interest on successful exits.

Product overview

quadraScope Ventures is a venture capital firm that invests in healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices enabling disease treatment and prevention through biological age reversal. As an investment fund, quadraScope does not offer products or services to end customers in the traditional sense. The company focuses on identifying and funding early-stage longevity biotechnology companies across various approaches including senolytics, cellular reprogramming, gene therapy, mitochondrial health, and regenerative medicine. The firm's portfolio includes investments in companies such as Immunis, BioChange, Aldens Scientific, MatterBio, Deciduous Therapeutics, Repair Biotechnologies, Vincere Bio, Cosmica, Healthy Longevity Clinic, AdvantAge Therapeutics, and BIOIO. The investment strategy is grounded in the Hallmarks of Aging scientific framework.

Differentiator

Problem solved

Functional benefit

Products and services

  • quadraScope Ventures Investment Fund Early-stage venture capital fund that provides equity capital, scientific due diligence, and strategic support to longevity biotechnology startups developing treatments targeting the Hallmarks of Aging. Limited partners commit capital; returns generated through exits.

Quantifiable outcome

  • 12x return on octoScope exit

Companies that use quadraScope

Customer profile

Named customers11 records

Segments1 record

Ideal customer profiles1 record

quadraScope technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

quadraScope partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered portfolio company, strategic and industry.

  • Klogenixportfolio companyOthersPortfolio company developing gene therapy using Klotho protein to treat aging and Alzheimer's disease. Co-founded by Carmela Abraham, PhD, who serves on quadraScope's Scientific Advisory Board and discovered that Klotho protein levels decrease with age and are neuroprotective.
  • SENS Research FoundationstrategicStrategic or Co-development PartnerBiomedical research charity focused on repairing molecular and cellular damage of aging. Scientific founder Aubrey de Grey serves on quadraScope's Scientific Advisory Board. SENS approach aligns with quadraScope's investment thesis on addressing hallmarks of aging.
  • Longevity Escape Velocity FoundationstrategicStrategic or Co-development PartnerFoundation led by Aubrey de Grey working on rejuvenation research. President & CSO noted that quadraScope encouraged formation of rejuvenation clinics and has been active in defining treatment protocols as strategic pillar alongside clinical trials.
  • Immunisportfolio companyOthersPortfolio company developing immune system restoration for muscle building, fat reduction, and treating obesity. Chairman Hans Keirstead cited strategic alignment with quadraScope's vision of extending lifespan and healthspan while treating diseases.
  • Healthy Longevity Clinicportfolio companyOthersPortfolio company operating franchise of clinics specializing in personalized rejuvenation treatments and offshore clinical trials. CEO Petr Sramek serves on quadraScope's Business Advisory Board.
  • Repair Biotechnologiesportfolio companyOthersPortfolio company developing cholesterol degradation platform to reverse atherosclerosis and fatty liver disease. Co-founder Reason serves on quadraScope's Scientific Advisory Board and is a long-standing investor in longevity industry.
  • Biomarkers of Aging ConsortiumindustryStrategic or Co-development PartnerConsortium established to develop reliable biomarkers of aging for identification and validation of longevity interventions. quadraScope presented posters at 2023 Biomarkers of Aging Symposium.
  • Longevity Biotechnology AssociationindustryOthersIndustry association for longevity biotechnology companies. quadraScope nominated to join in November 2022.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

quadraScope competitors and assessment

Company assessment

Direct peers

  • Apollo Health Ventures: Early-stage VC investing specifically in longevity and aging biotech, mirroring quadraScope's thesis on hallmarks-of-aging interventions.
  • Kizoo Technology Ventures: Germany-based seed investor dedicated to rejuvenation biotech startups, directly comparable in stage and longevity focus.
  • LongeVC: Early-stage venture fund backing longevity and biotech founders, sharing quadraScope's specialist focus and stage.
  • Longevity Vision Fund: Sergey Young's fund investing in technologies that extend healthy human lifespan, directly overlapping quadraScope's sector thesis.
  • Methuselah Fund: Mission-driven fund investing in companies extending healthspan, closely aligned with quadraScope's rejuvenation focus.
  • Age1: Seed-stage fund and accelerator (successor to The Longevity Fund) focused on aging biology startups, a direct longevity-specialist peer.
  • R42 Group: AI and longevity-focused venture fund backing aging and healthspan startups, overlapping quadraScope's investment domain.

Regional players

  • Maximon: Swiss longevity company builder and investor in healthy-aging ventures; comparable thesis but centered in Europe.

Emerging players

  • Cambrian Biopharma: Builds and funds a portfolio of aging-disease therapeutics companies, overlapping quadraScope's longevity portfolio approach via a different (build) model.

Broad incumbents

  • Juvenescence: Larger longevity-focused company builder and investor developing aging therapeutics, operating broadly across the same rejuvenation space as quadraScope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

quadraScope social profiles

Digital presence

quadraScope financial estimates

Financial estimate

Revenue estimate

Valuation estimate

quadraScope leadership team

Management profile

Number of profiles

Profiles18 records

quadraScope funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

quadraScope M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about quadraScope

What does quadraScope do?

quadraScope Ventures is a venture capital firm that invests in early-stage healthcare companies developing pharmaceuticals, diagnostics, software, equipment, and devices that enable disease treatment and prevention through biological age reversal. The firm manages capital and deploys equity into longevity biotechnology startups, provides strategic guidance and scientific due diligence, and supports portfolio companies in clinical development and regulatory pathways. Revenue is generated through management fees and carried interest on successful exits.

Is quadraScope a public or private company?

quadraScope is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was quadraScope founded?

quadraScope was founded in 2022. It employs 1 to 10 people.

Where is quadraScope based?

quadraScope is headquartered in Boston, United States, in the North America region.

How does quadraScope make money?

One revenue line is on record: venture Capital Fund Management.

Who are quadraScope's main competitors?

Direct peers on record are Apollo Health Ventures, Kizoo Technology Ventures, LongeVC, Longevity Vision Fund, Methuselah Fund, Age1 and R42 Group. Maximon is listed as a regional player. Cambrian Biopharma is listed as an emerging player. Juvenescence is listed as a broad incumbent.

Does quadraScope have an API?

No public API is recorded for quadraScope.

What industry is quadraScope in?

quadraScope's product category is Venture Capital - Longevity Biotechnology. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales